INBS (INBS) director receives 5,000 restricted shares in equity award

Rhea-AI Filing Summary

Boyages Steven Constantine reported acquisition or exercise transactions in this Form 4 filing.

INTELLIGENT BIO SOLUTIONS INC. director Steven Constantine Boyages received a grant of 5,000 restricted shares of Common Stock on March 18, 2026 under the company’s 2019 Long Term Incentive Plan. These shares vest after 12 months and may be forfeited if vesting conditions are not met. Following this equity award, Boyages holds 5,031 common shares directly. All amounts are presented on a post–1-for-10 reverse stock split basis after the company’s December 15, 2025 reverse split.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Boyages Steven Constantine

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	5,000	$0.00	--

Holdings After Transaction: Common Stock — 5,031 shares (Direct)

Footnotes (1)

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boyages Steven Constantine

(Last) (First) (Middle)

C/O INTELLIGENT BIO SOLUTIONS INC.,

135 WEST 41ST STREET, 5TH FLOOR

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTELLIGENT BIO SOLUTIONS INC. [ INBS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/18/2026		A		5,000(2)	A	$0	5,031(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On December 15, 2025, Intelligent Bio Solutions Inc. (the "Issuer") effected a 1-for-10 reverse stock split of the Issuer's common stock ("Common Stock"). The reverse stock split effected in December 2025, and prior reverse stock splits effected by the Issuer, resulted in a reduction in the number of shares held by the reporting person and proportional adjustments to the outstanding equity awards held by the reporting person. Accordingly, all amounts in this Form 4 are presented on a post-reverse split basis.

2. On March 18, 2026, the Issuer granted the reporting person 5,000 restricted shares of Common Stock under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. The awarded shares are subject to time-based vesting after 12 months and are subject to forfeiture until vested.

	/s/ Steven Constantine Boyages	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INBS director Steven Boyages report?

Director Steven Boyages reported receiving a grant of 5,000 restricted shares of INBS Common Stock. The award was made as equity compensation, not a market purchase, and increases his direct holdings to 5,031 shares after the transaction.

When do the 5,000 restricted INBS shares granted to Steven Boyages vest?

The 5,000 restricted INBS shares granted to Steven Boyages are subject to time-based vesting after 12 months. Until they vest, the shares are subject to forfeiture, meaning he could lose them if vesting conditions are not satisfied.

Under which plan were Steven Boyages’s 5,000 INBS restricted shares granted?

The 5,000 restricted INBS shares granted to Steven Boyages were issued under the Intelligent Bio Solutions Inc. 2019 Long Term Incentive Plan. This plan provides equity-based compensation, aligning director incentives with the company’s common stock performance over time.

How many INBS shares does Steven Boyages own after this Form 4 transaction?

After the reported grant, Steven Boyages directly holds 5,031 shares of INBS Common Stock. This figure reflects his position following the 5,000-share restricted stock award and is presented on a post–reverse stock split basis, as disclosed.

How did INBS’s December 2025 reverse stock split affect Steven Boyages’s reported holdings?

INBS completed a 1-for-10 reverse stock split on December 15, 2025, reducing the number of shares outstanding. The filing explains that all amounts, including Boyages’s holdings and awards, are reported on a post–reverse split basis for consistency.